Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Roche/Ipsen's Suspended Taspoglutide Could Be Another Diabetes Casualty

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Roche's decision to halt dosing in a trial of the GLP-1 receptor agonist taspoglutide following an announcement of a major development delay illustrates the intensively competitive nature of the diabetes market

You may also be interested in...

Roche Announces Internal Review Likely To Result In Staff, Program Cuts

Swiss pharma cites U.S. and EU health care spending constraints and regulatory setbacks as reasons for plan.

Phenomix Folds After Diabetes Drug Fails To Attract Partner To Fill Forest's Shoes

DPP-4 drug dutogliptin was a casualty of the highly competitive, regulated and expensive space for diabetes drug development.

Roche's Wildcard GLP-1 Not A Spoiler After All; Amylin Stock Soars On Taspoglutide Setback

Roche has voluntarily initiated a risk mitigation strategy to identify patients likely to develop troublesome hypersensitivity reactions and estimates a 12-18 month delay in the development program for the type 2 diabetes therapy.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts